Impact of angiotensin receptor-neprilysin inhibition (ARNI) in improving ejection fraction and left and right ventricular remodeling in heart failure
- 16 February 2024
- journal article
- review article
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (4) , 102464
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Dynamic Changes in Myocardial Matrix and Relevance to DiseaseCirculation Research, 2014
- Right Heart Adaptation to Pulmonary Arterial HypertensionJACC, 2013
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialThe Lancet, 2012
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failureDrug Discovery Today: Therapeutic Strategies, 2012
- Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection FractionJACC, 2010
- The Right Ventricle Under PressureChest, 2009
- TGFβ, cardiac fibroblasts, and the fibrotic responseCardiovascular Research, 2007
- Long-Term Trends in the Incidence of and Survival with Heart FailureNew England Journal of Medicine, 2002
- Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodelingJACC, 2000